GILD - Gilead Records Positive Phase III Results In HIV
2024-06-22 03:56:43 ET
Summary
- Gilead Sciences reports positive Phase III trial results for lenacapavir, showing zero incident cases of HIV infection in the treatment group.
- Results suggest the potential for lenacapavir to revolutionize HIV prevention and treatment, leading to market expansion and creating shareholder value.
- Gilead's diversified revenue streams from HIV, liver disease, COVID-19, and oncology products position the company for continued growth and success.
Gilead Sciences (GILD) on Thursday announced positive topline results from an interim analysis of its Phase III PURPOSE 1 trial. The trial which tested the efficacy of twice-yearly lenacapavir versus once daily Truvada and Descovy in approximately 5,300 women at risk of contracting HIV in South Africa and Uganda, found 0 incident cases of HIV infection in the lenacapavir group. In other words, among the 2,124 treated with twice yearly subcutaneous lenacapavir, none tested positive for the HIV virus....
Gilead Records Positive Phase III Results In HIV